MedTrace Logo

Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL

NCT04303520 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-03-11

No results posted yet for this study

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/CD22 bispecific chimeric antigen receptors (CARs) T cell therapy for CD19-positive Acute Lymphoblastic Leukemia.

Conditions

  • CD19-positive ALL

Interventions

BIOLOGICAL

anti-CD19/CD22 CAR-T cells

Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs

DRUG

Fludarabine

30mg/m2/d

DRUG

Cyclophosphamide

500mg/m2/d

Sponsors & Collaborators

  • Hrain Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    collaborator OTHER

  • The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-03
Primary Completion
2020-09-30
Completion
2021-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303520 on ClinicalTrials.gov